Clinical features and prognosis of patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, S. H. | - |
dc.contributor.author | Park, J. S. | - |
dc.contributor.author | Kim, S. Y. | - |
dc.contributor.author | Kim, D. S. | - |
dc.contributor.author | Kim, Y. W. | - |
dc.contributor.author | Chung, M. P. | - |
dc.contributor.author | Uh, S. T. | - |
dc.contributor.author | Park, C. S. | - |
dc.contributor.author | Park, S. W. | - |
dc.contributor.author | Jeong, S. H. | - |
dc.contributor.author | Park, Y. B. | - |
dc.contributor.author | Lee, H. L. | - |
dc.contributor.author | Shin, J. W. | - |
dc.contributor.author | Lee, J. H. | - |
dc.contributor.author | Jegal, Y. | - |
dc.contributor.author | Lee, H. K. | - |
dc.contributor.author | Kim, Y. H. | - |
dc.contributor.author | Song, J. W. | - |
dc.contributor.author | Park, M. S. | - |
dc.date.available | 2020-02-27T02:42:36Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-06-01 | - |
dc.identifier.issn | 1027-3719 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1379 | - |
dc.description.abstract | BACKGROUND: Idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD) share common risk factors. They could therefore be expressed in a single patient. However, the prevalence, clinical characteristics and prognosis of individuals with comorbid IPF and COPD are not known. METHOD: From 2003 to 2007, the Korean Interstitial Lung Disease Study Group created a register for idiopathic interstitial pneumonia using 2002 ATS/ERS (American Thoracic Society/European Respiratory Society) criteria. Of the 1546 IPF patients assessed, 143 had decreased lung function consistent with COPD (IPF-COPD). COPD was diagnosed based on age (>= 40 years) and pulmonary function (forced expiratory volume in 1 sec [FEV1]/forced vital capacity [FVC] ratio < 0.7). RESULTS : The median age of the IPF-COPD group was 71.0 years (interquartile range 66.0-76.0); most patients were male (88.1%). FVC (%) was significantly higher in the IPF-COPD group; however, FEV1 (%) was significantly lower in the IPF-COPD group (P < 0.001). Diffusing capacity of the lung for carbon monoxide (DLCO) was not significantly different between the two groups. In survival analysis, age and FVC (%), but not COPD, were significantly associated with prognosis (respectively P = 0.003, 0.001 and 0.401). COPD severity was also not related to prognosis (P = 0.935). CONCLUSION: The prevalence of IPF-COPD was estimated to be similar to 9.2% among all IPF patients; prognosis of patients with IPF-COPD was not worse than those with IPF alone. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | - |
dc.subject | LUNG-CANCER | - |
dc.subject | EMPHYSEMA | - |
dc.subject | DIAGNOSIS | - |
dc.subject | IMPACT | - |
dc.subject | CLASSIFICATION | - |
dc.subject | PIRFENIDONE | - |
dc.subject | SURVIVAL | - |
dc.subject | COPD | - |
dc.title | Clinical features and prognosis of patients with idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000476473700006 | - |
dc.identifier.doi | 10.5588/ijtld.18.0194 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, v.23, no.6, pp.678 - 684 | - |
dc.identifier.scopusid | 2-s2.0-85071505096 | - |
dc.citation.endPage | 684 | - |
dc.citation.startPage | 678 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE | - |
dc.citation.volume | 23 | - |
dc.citation.number | 6 | - |
dc.contributor.affiliatedAuthor | Jeong, S. H. | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | chronic obstructive pulmonary fibrosis | - |
dc.subject.keywordAuthor | IPF | - |
dc.subject.keywordAuthor | prognosis | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | EMPHYSEMA | - |
dc.subject.keywordPlus | DIAGNOSIS | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | PIRFENIDONE | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | COPD | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalResearchArea | Respiratory System | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Respiratory System | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.